ArticleMolecular vision2017
Meclofenamic acid improves the signal to noise ratio for visual responses produced by ectopic expression of human rod opsin.
Article in Molecular vision, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 11 citations in OpenAlex.
- Functional methods for evaluating the efficacy of retinal optogenetic therapy for vision restoration.Frontiers in neuroscience · 2026Review
- Robotising vitreoretinal surgeries.Eye (London, England) · 2025Review
- Advantages of human opsins in optogenetic visual restoration.Frontiers in neuroscience · 2025Review
- Bioengineering strategies for restoring vision.Nature biomedical engineering · 2023Review
- Optogenetic Therapy for Visual Restoration.International journal of molecular sciences · 2022Review
- A systematic comparison of optogenetic approaches to visual restoration.Molecular therapy. Methods & clinical development · 2022Article
- Stage-Dependent Changes of Visual Function and Electrical Response of the Retina in theFrontiers in cellular neuroscience · 2022Article
- Correlated Activity in the Degenerate Retina Inhibits Focal Response to Electrical Stimulation.Frontiers in cellular neuroscience · 2022Article
- Optogenetic Gene Therapy for the Degenerate Retina: Recent Advances.Frontiers in neuroscience · 2020Review
- Molecular Therapies for Choroideremia.Genes · 2019Review
- Molecular Strategies for RPGR Gene Therapy.Genes · 2019Review
- Article
- Progress in the development of novel therapies for choroideremia.Expert review of ophthalmology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
purposeRetinal dystrophy through outer photoreceptor cell death affects 1 in 2,500 people worldwide with severe impairment of vision in advanced stages of the disease. Optogenetic strategies to restore visual function to animal models of retinal degeneration by introducing photopigments to neurons spared degeneration in the inner retina have been explored, with variable degrees of success. It has recently been shown that the non-steroidal anti-inflammatory and non-selective gap-junction blocker meclofenamic acid (MFA) can enhance the visual responses produced by an optogenetic actuator (channelrhodopsin) expressed in retinal ganglion cells (RGCs) in the degenerate retina. Here, we set out to determine whether MFA could also enhance photoreception by another optogenetic strategy in which ectopic human rod opsin is expressed in ON bipolar cells.
methodsWe used in vitro multielectrode array (MEA) recordings to characterize the light responses of RGCs in the
resultsWe found treated retinas were light responsive over five decades of irradiance (from 10
conclusionsThese results confirm the potential of MFA to inhibit spontaneous activity and enhance the signal to noise ratio of visual responses in optogenetic therapies to restore sight.
Indexed as
Identifiers
28659709PMC5479694W2744672903What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.